OnCURE Medical Corp. Announces the Appointment of David S. Chernow to the Board of Directors of OnCURE Holdings, Inc.

NEWPORT BEACH, Calif. -- OnCURE Medical Corp. ("OnCURE"), a leading provider of outpatient radiation therapy services, today announced the appointment of David S. Chernow to the Board of Directors of its parent corporation, OnCURE Holdings, Inc. Mr. Chernow joins Dr. Shyam Paryani (Chairman), Jeffrey Goffman, James Nadauld, Robert Weltman and Richard Zehner on the Board of Directors of OnCURE Holdings, Inc.

Richard Zehner, OnCURE's Chief Executive Officer, stated, "We are excited about Mr. Chernow joining the Board of Directors. David's prior experience in the oncology sector will provide OnCURE with valuable insight with respect to growth and management as OnCURE continues to execute its strategic acquisition and development plans."

David S. Chernow has held the position of global President and Chief Executive Officer of JA Worldwide([TM]) (Junior Achievement) since January 2005. Beginning in July 2001, Mr. Chernow was appointed President and CEO of Junior Achievement Inc., responsible for leading the United States organization. Mr. Chernow was previously President of the Physician Services Group at US Oncology from 1990 to 2001, and was responsible for development and operations for a network of more than 850 physicians in 26 states, with 74 comprehensive cancer centers and 8,000 employees at the time of his departure in 2001. Mr. Chernow was co-founder of American Oncology Resources (AOR) in 1992, and served as Chief Development Officer of AOR prior to the merger in 1999 between AOR and another company which led to the formation of US Oncology. Mr. Chernow earned his J.D. at Pepperdine University and his undergraduate degree from UCLA.

About OnCURE

OnCURE owns, operates and manages 33 radiation centers and other mobile HDR & PET/CT units, all located in California and Florida. OnCURE's centers provide treatment areas and equipment for radiation therapy and diagnostic radiology, including IMRT, CT and PET. OnCURE provides capital, technology, and management expertise to its affiliated physician groups (approximately 55 doctors), including clinical management, billing and collection, data warehousing, accounting, compliance and other administrative services. OnCURE has approximately 350 employees. For more information, visit www.OnCURE.com.

About Genstar Capital, LLC.

Based in San Francisco, Genstar Capital (www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle-market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $900 million of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of the health care services, life sciences, business services, and industrial technology sectors.

Forward-Looking Statements

Statements in this Press Release that are not historical facts constitute "forward-looking statements." Any statements contained herein which are not historical facts or which contain the words "anticipate," "believe," "continue," "estimate," "expect," "intend," "may," "should," and similar expressions are intended to identify forward-looking statements. Such statements reflect the current view of OnCURE with respect to future events and are subject to certain risks, uncertainties and assumptions, including, but not limited to, the risk that OnCURE may not be able to implement its growth strategy in the intended manner, including the ability to identify, finance, complete and integrate acquisitions and joint venture opportunities, risks regarding currently unforeseen competitive pressures and risks affecting OnCURE's industry, such as increased regulatory compliance and changes in regulatory requirements, changes in payor reimbursement levels and the development of additional alternative treatment modalities and technological changes. Should one or more of those risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein.